Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
+$1B |
| 2 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$546M |
| 3 |
Alibaba
BABA
|
+$482M |
| 4 |
AGN
Allergan plc
AGN
|
+$478M |
| 5 |
Perrigo
PRGO
|
+$292M |
Top Sells
| 1 |
Alphabet (Google) Class C
GOOG
|
+$763M |
| 2 |
Merck
MRK
|
+$745M |
| 3 |
AGN
ALLERGAN INC
AGN
|
+$612M |
| 4 |
TJX Companies
TJX
|
+$561M |
| 5 |
Schlumberger
SLB
|
+$511M |
Sector Composition
| 1 | Healthcare | 19.13% |
| 2 | Consumer Discretionary | 14.47% |
| 3 | Technology | 12.22% |
| 4 | Communication Services | 11.74% |
| 5 | Financials | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LMOS
476
DELISTED
Lumos Networks Corp
LMOS
| $11.3M | 0.01% |
671,602
-421,882
| -39% | -$7.1M |
|
|
WBC
477
DELISTED
WABCO HOLDINGS INC.
WBC
| $10.8M | 0.01% |
103,535
-211,558
| -67% | -$22.2M |
|
|
EGRX
478
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $10.7M | 0.01% |
688,843
-551
| -0.1% | -$8.54K |
|
|
ANAC
479
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $10.7M | 0.01% |
+330,836
| New | +$10.7M |
|
|
DSCI
480
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $10.6M | 0.01% |
1,136,666
-12,648
| -1% | -$118K |
|
|
DBVT
481
DBV Technologies
DBVT
$260M
| $10.1M | 0.01% |
+37,257
| New | +$10.1M |
|
|
CBAY
482
DELISTED
Cymabay Therapeutics
CBAY
| $9.77M | 0.01% |
993,500
-6,500
| -0.7% | -$63.9K |
|
483
Qualys
QLYS
$4.75B
| $9.52M | 0.01% |
252,092
-106,378
| -30% | -$4.02M |
|
|
DERM
484
DELISTED
Dermira, Inc.
DERM
| $9.49M | 0.01% |
+523,978
| New | +$9.49M |
|
485
Madrigal Pharmaceuticals
MDGL
$9.59B
| $9.35M | 0.01% |
100,852
-4,116
| -4% | -$382K |
|
486
Larimar Therapeutics
LRMR
$342M
| $9.01M | 0.01% |
24,338
-9,342
| -28% | -$3.46M |
|
487
Tandem Diabetes Care
TNDM
$836M
| $8.89M | 0.01% |
69,997
-57,207
| -45% | -$7.27M |
|
|
SPNC
488
DELISTED
Spectranetics Corp
SPNC
| $8.87M | 0.01% |
+256,456
| New | +$8.87M |
|
489
Q2 Holdings
QTWO
$5.13B
| $8.71M | 0.01% |
+462,285
| New | +$8.71M |
|
490
MPLX
MPLX
$50.8B
| $8.38M | 0.01% |
113,977
-66,365
| -37% | -$4.88M |
|
|
PSXP
491
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $8.18M | 0.01% |
118,734
-54,258
| -31% | -$3.74M |
|
492
NETSCOUT
NTCT
$1.8B
| $7.95M | 0.01% |
217,551
-288,665
| -57% | -$10.5M |
|
493
Atara Biotherapeutics
ATRA
$82.7M
| $7.86M | 0.01% |
+11,748
| New | +$7.86M |
|
494
Assembly Biosciences
ASMB
$171M
| $7.03M | 0.01% |
74,493
+41,160
| +123% | +$3.88M |
|
|
FCSC
495
DELISTED
Fibrocell Science Inc.
FCSC
| $6.86M | 0.01% |
178,646
-5,674
| -3% | -$218K |
|
496
Enbridge
ENB
$106B
| $6.83M | 0.01% |
132,826
-1,120,173
| -89% | -$57.6M |
|
|
RGLS
497
DELISTED
Regulus Therapeutics
RGLS
| $6.45M | 0.01% |
3,351
+658
| +24% | +$1.27M |
|
|
ETP
498
DELISTED
Energy Transfer Partners L.p.
ETP
| $6.31M | 0.01% |
97,138
+24,499
| +34% | +$1.59M |
|
499
National Grid
NGG
$70.1B
| $5.95M | 0.01% |
86,020
+23,365
| +37% | +$1.62M |
|
|
NVRO
500
DELISTED
NEVRO CORP.
NVRO
| $5.68M | 0.01% |
+146,875
| New | +$5.68M |
|